The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: A decision analysis

American Journal of Medicine

Volumn 116, Issue 7, 2004, Pages 451-459

  Gerson, Lauren B ^a,c   Triadafilopoulos, George ^a   Gage, Brian F ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; COLONOSCOPY; COST UTILITY ANALYSIS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; HEALTH CARE FINANCING; HEART ATRIUM FIBRILLATION; INTERMETHOD COMPARISON; PHYSICAL MODEL; POLYPECTOMY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SCREENING TEST; SURVIVAL RATE; TREATMENT WITHDRAWAL;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; DISEASE MANAGEMENT; ENDOSCOPY, GASTROINTESTINAL; HEMORRHAGE; HUMANS; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; THROMBOPHILIA; TREATMENT OUTCOME; WARFARIN;

EID: 1642366382     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.10.035     Document Type: Article

References (80)

1. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastrointest Endosc. 2002;55:775-779.
2. Gerson L.B., Gage B.F., Owens D.K., Triadafilopoulos G. Effect and outcomes of the ASGE guidelines on the periendoscopic management of patients who take anticoagulants. Am J Gastroenterol. 95:2000;1717-1724.
3. Marietta M., Bertesi M., Simoni L., et al. A simple and safe nomogram for the management of oral anticoagulation prior to minor surgery. Clin Lab Haematol. 25:2003;127-130.
4. Russell L.B., Gold M.R., Siegel J.E., et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 276:1996;1172-1177.
5. Gage B.F., Cardinalli A.B., Albers G.W., Owens D.K. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 274:1995;1839-1845.
6. Gage B.F., Cardinalli A.B., Owens D.K. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke. 29:1998;1083-1091.
7. Milligan P.E., Banet G.A., Gage B.F. Peri-operative reduction of the warfarin dose. Am J Med. 115:2003;741-742.
8. Tinmouth A.H., Morrow B.H., Cruickshank M.K., et al. Dalteparin as peri-procedure anticoagulation for patients on warfarin and at high risk of thrombosis. Ann Pharmacother. 35:2001;669-674.
9. White R.H., McKittrick T., Hutchinson R., Twitchell J. Temporary discontinuation of warfarin therapy changes in the international normalized ratio. Ann Intern Med. 122:1995;40-42.
10. Harrison L., Johnston M., Massicotte P., et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med. 126:1997;133-136.
11. Beyth R.J., Quinn L.M., Landefeld C.S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 105:1998;91-99.
12. White R.H., Beyth R.J., Zhou H., Romano P.S. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med. 107:1999;414-424.
13. Hart R.G., Benavente O., McBride R., Pearce L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation a meta-analysis. Ann Intern Med. 131:1999;492-501.
14. Palareti G., Legnani C. Warfarin withdrawal. Pharmacokinetic- pharmacodynamic considerations. Clin Pharmacokinet. 30:1996;300-313.
15. Francis C.W., Pellegrini V.D., Leibert K.M., et al. Comparison of two warfarin regimens in the prevention of venous thrombosis following total knee replacement. Thromb Haemost. 75:1996;706-711.
16. Orsoni P., Berdah S., Verrier C., et al. Colonic perforation due to colonoscopy a retrospective study of 48 cases. Endoscopy. 29:1997;160-164.
17. Winawer S.J., Fletcher R.H., Miller L., et al. Colorectal cancer screening clinical guidelines and rationale. Gastroenterology. 112:1997;594-642.
18. Williams A.R., Balasooriya B.A.W., Day D.W. Polyps and cancer of the large bowel a necropsy study in Liverpool. Gut. 123:1982;835-842.
19. Connolly S.J., Laupacis A., Gent M., et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol. 18:1991;349-355.
20. Laupacis A., Singer D., Jacobsen A., et al. Risk factors for stroke and primary prevention of stroke in atrial fibrillation. J Thromb Thrombolysis. 7:1999;21-26.
21. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. JAMA. 1998;279:1273-1277
22. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-691
23. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med. 154:1994;1449-1457.
24. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical prediction rules for stroke results from the National Registry of Atrial Fibrillation (NRAF) project. JAMA. 285:2001;2864-2870.
25. Hart R.G., Benavente O., McBride R., Pearce L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation a meta-analysis. Ann Intern Med. 131:1999;492-501.
26. Harenberg J., Weuster B., Pfitzer M., et al. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin. Semin Thromb Hemost. 19:1993;116-121.
27. Ross S. A First Course in Probability. 3rd ed:1988;Macmillan Publishing Company, New York, New York.
28. Evans A., Perez I., Yu G., Kalra L. Secondary stroke prevention in atrial fibrillation lessons from clinical practice. Stroke. 31:2000;2106-2111.
29. Hylek E.M., Chang Y.C., Skates S.J., et al. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med. 160:2000;1612-1617.
30. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation a multicenter, prospective, randomized trial. Japanese nonvalvular atrial fibrillation-embolism secondary prevention cooperative study group. Stroke. 31:2000;817-821.
31. Gullov A.L., Koefoed B.G., Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation the AFASAK 2 study. Atrial fibrillation aspirin and anticoagulation. Arch Intern Med. 159:1999;1322-1328.
32. Ezekowitz M.D., Bridgers S.L., James K.E., et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs stroke prevention in nonrheumatic atrial fibrillation investigators. N Engl J Med. 328:1992;1406-1412.
33. Feinberg W.M., Kronmal R.A., Newman A.B., et al. Stroke risk in an elderly population with atrial fibrillation. J Gen Intern Med. 14:1999;56-59.
34. Landefeld C.S., Beyth R.J. Anticoagulant-related bleeding clinical epidemiology, prediction, and prevention. Am J Med. 95:1993;315-328.
35. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet. 1998;351:233-241
36. Antman E.M., McCabe C.H., Gurfinkel E.P., et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 100:1999;1593-1601.
37. Gilbert K.B., Rodgers G.M. Utilization and outcomes of enoxaparin treatment for deep-vein thrombosis in a tertiary-care hospital. Am J Hematol. 65:2000;285-288.
38. Shaieb M.D., Watson B.N., Atkinson R.E. Bleeding complications with enoxaparin for deep venous prophylaxis. J Arthoplasty. 14:1999;423-428.
39. Rocha E., Martinez-Gomez M.A., et al. Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis. Haematologica. 85:2000;935-942.
40. Heit J.A., Elliott C.G., Trowbridge A.A., et al. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 132:2000;853-861.
41. Katholi R.E., Nolan S.P., McGuire L.B. The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves. Am Heart J. 96:1978;163-165.
42. Zidane M., Schram M.T., Planken E.W., et al. Frequency of major hemorrhage in patients treated with unfractionated intravenous heparin for deep venous thrombosis or pulmonary embolism a study in routine clinical practice. Arch Intern Med. 160:2000;2369-2373.
43. Levine M., Gent M., Hirsh J., et al. A comparison of low-molecular- weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 334:1996;677-681.
44. Merli G., Spiro T.E., Olsson C.G., et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 134:2001;191-202.
45. Reed D.N. Jr, Collins J.D., Wyatt W.J., et al. Can general surgeons perform colonoscopy safely? Am J Surg. 163:1992;257-259.
46. Kavic S.M., Basson M.D. Complications of endoscopy. Am J Surg. 181:2001;319-332.
47. Waye J.D., Kahn O., Auerbach M.E. Complications of colonoscopy and flexible sigmoidoscopy. Gastrointest Endosc Clin North Am. 6:1996;343-377.
48. Schauer P.R., Schwesinger W.H., Page C.P., et al. Complications of surgical endoscopy. A decade of experience from a surgical residency training program. Surg Endosc. 11:1997;8-11.
49. Shiffman M.L., Farrel M.T., Yee Y.S. Risk of bleeding after endoscopic biopsy or polypectomy in patients taking aspirin or other NSAIDS. Gastrointest Endosc. 40:1994;458-462.
50. Parra-Blanco A., Kaminaga N., Kojima T., et al. Colonoscopic polypectomy with cutting current is it safe? Gastrointest Endosc. 51:2000;676-681.
51. Mann N.S., Mann S.K., Alam I. The safety of hot biopsy forceps in the removal of small colonic polyps. Digestion. 60:1999;74-76.
52. Gibbs D.H., Opelka F.G., Beck D.E., et al. Postpolypectomy colonic hemorrhage. Dis Colon Rectum. 39:1996;806-810.
53. Nivatvongs S. Complications in colonoscopic polypectomy. An experience with 1,555 polypectomies. Dis Colon Rectum. 29:1986;825-830.
54. Parra-Blanco A., Kaminaga N., Kojima T., et al. Hemoclipping for postpolypectomy and postbiopsy colonic bleeding. Gastrointest Endosc. 51:2000;37-41.
55. Rosen L., Bub D.S., Reed J.F. III, Nastasee S.A. Hemorrhage following colonoscopic polypectomy. Dis Colon Rectum. 36:1993;1126-1131.
56. Rabenstein T., Schneider H.T., Bulling D., et al. Analysis of the risk factors associated with endoscopic sphincterotomy techniques preliminary results of a prospective study, with emphasis on the reduced risk of acute pancreatitis with low-dose anticoagulation treatment. Endoscopy. 32:2000;10-19.
57. Loperfido S., Angelini G., Benedetti G., et al. Major early complications from diagnostic and therapeutic ERCP a prospective multicenter study. Gastrointest Endosc. 48:1998;1-10.
58. Freeman M.L., Nelson D.B., Sherman S., et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med. 335:1996;909-918.
59. Winawer S.J., Fletcher R.H., Miller L., et al. Colorectal cancer screening clinical guidelines and rationale. Gastroenterology. 112:1997;594-642.
60. Waye J.D., Lewis B.S., Yessayan S. Colonoscopy a prospective report of complications. J Clin Gastroenterol. 15:1992;347-351.
61. Palareti G., Legnani C., Guazzaloca G., et al. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants - a prospective study. Thromb Haemost. 72:1994;222-226.
62. White R., McKittrick T., Takakuwa J., et al. Management and prognosis of life-threatening bleeding during warfarin therapy. Arch Intern Med. 156:1996;1197-1201.
63. Kuwada S.K., Blam R., Gostout C.J. The role of withdrawing chronic anticoagulation because of acute GI bleeding. Am J Gastroenterol. 91:1996;1116-1119.
64. Czernichow P., Hochain P., Nousbaum J.B., et al. Epidemiology and course of acute upper gastro-intestinal haemorrhage in four French geographical areas. Eur J Gastroenterol Hepatol. 12:2000;175-181.
65. Longstreth G.F. Epidemiology and outcome of patients hospitalized with acute lower gastrointestinal hemorrhage a population-based study. Am J Gastroenterol. 92:1997;419-424.
66. Rockall T.A., Logan R.F., Devlin H.B., Northfield T.C. Variation in outcome after acute upper gastrointestinal haemorrhage. The national audit of acute upper gastrointestinal haemorrhage. Lancet. 346:1995;346-350.
67. Drug Topics Red Book. 2000;Spectrum Health, Montvale, New Jersey.
68. Fryback D.G., Dasbach E.J., Klein R., et al. The Beaver Dam Health Outcomes study initial catalog of health-state quality factors. Med Decis Making. 13:1993;89-102.
69. Thomson R., Parkin D., Eccles M., et al. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet. 355:2000;956-962.
70. Bini E.J., Firoozi B., Choung R.J., et al. Systematic evaluation of complications related to endoscopy in a training setting A prospective 30-day outcomes study. Gastrointest Endosc. 57:2003;8-16.
71. Shafer A. Complications of sedation with midazolam in the intensive care unit and a comparison with other sedative regimens. Crit Care Med. 26:1998;947-956.
72. Siegel J.E., Weinstein M.C., Russell L.B., Gold M.R. Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. JAMA. 276:1996;1339-1341.
73. Gage B.F., Cardinallli A.B., Owens D.K. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 156:1996;1829-1836.
74. Rex D.K., Lewis B.S., Waye J.D. Colonoscopy and endoscopic therapy for delayed post-polypectomy hemorrhage. Gastrointest Endosc. 38:1992;127-129.
75. Sorbi D., Norton I., Conio M., et al. Postpolypectomy lower GI bleeding descriptive analysis. Gastrointest Endosc. 51:2000;690-696.
76. Wahl M.J. Myths of dental surgery in patients receiving anticoagulant therapy. J Am Dent Assoc. 131:2000;77-81.
77. Cannegieter S.C., Rosendaal F.R., Wintzen A.R., et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 333:1995;11-17.
78. Eckman M.H., Beshansky J.R., Durand-Zaleski I., et al. Anticoagulation for noncardiac procedures in patients with prosthetic heart valves. Does low risk mean high cost? JAMA. 263:1990;1513-1521.
79. Kearon C., Hirsh J. Management of anticoagulation before and after elective surgery. N Eng J Med. 336:1997;1506-1511.
80. Eckman M.H. Patient-centered decision making a view of the past and look toward the future. Med Decis Making. 21:2001;241-247.